Home / Market News / $NTRA

$NTRA news and market catalysts

The 49 most recent market catalysts affecting $NTRA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

49 catalysts 8 high impact 40 bullish 1 bearish Biotechnology
Nov 17, 2026 Corporate Catalyst Bullish Impact 55
Natera Named Best-in-Class Winner at Digital Health Hub Foundation Awards
Natera, Inc. was recognized as the 'Best in Class' winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards for it…
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
Natera and Incyte Announce Clinical Collaboration for Phase II Colorectal Cancer Study
Natera and Incyte have formed a clinical collaboration to conduct a Phase II study for stage 2/3 colorectal cancer patients. This partnership is significant as it integrates Natera…
Nov 10, 2026 Corporate Catalyst Bullish Impact 65
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Natera has entered a clinical collaboration with Incyte to conduct a Phase II study for stage 2/3 colorectal cancer patients. This study will evaluate Incyte's investigational immu…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
Roth MKM Adjusts Natera Price Target
Roth MKM analyst Max Masucci adjusted Natera's (NTRA) price target from $475 to $405, representing a significant reduction. While the 'Buy' rating was maintained, the lower price t…
Nov 9, 2026 Corporate Catalyst Bullish Impact 55
Baird Maintains Natera Buy Rating and Raises Price Target
Baird analyst Catherine Ramsey Schulte maintained a 'Buy' rating on Natera (NTRA) and raised the price target from $348 to $403. This action signals increased confidence from a not…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Natera Reports Third Quarter 2026 Financial Results
Natera announced its third-quarter 2026 financial results, revealing a substantial increase in total revenue to $794.0 million from $592.2 million in the prior year, alongside a gr…
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Natera Announces Leadership Transition
Natera, Inc. has announced a significant leadership change, with Solomon Moshkevich taking over as CEO from Steve Chapman. This transition is important because a change in top lead…
Nov 5, 2026 Corporate Catalyst Neutral Impact 55
Natera to Present New Signatera Data at SITC Annual Meeting
Natera is presenting new data on its Signatera test at a significant industry conference (SITC). The data highlights the test's ability to monitor ctDNA clearance during first-line…
Nov 5, 2026 Corporate Catalyst Bearish Impact 65
Natera Wins $19.3 Million Patent Infringement Verdict Against ArcherDX
Natera (NTRA) successfully won a $19.3 million patent infringement lawsuit against ArcherDX, a subsidiary of Invitae (NVTA). This verdict is significant as it validates Natera's in…
Nov 4, 2026 Corporate Catalyst Bullish Impact 65
Natera Announces Three New Peer-Reviewed Publications for Signatera in Head and Neck Cancer
Natera announced the publication of three peer-reviewed studies in prominent medical journals, validating the clinical performance of its Signatera cell-free DNA test for head and …
Nov 3, 2026 Corporate Catalyst Bullish Impact 75
Natera Receives Medicare Coverage for Signatera MRD Test in Hepatocellular Carcinoma
Natera announced that its Signatera molecular residual disease (MRD) test for hepatocellular carcinoma (HCC) has secured Medicare coverage through the MolDX program. This is a sign…
Oct 27, 2026 Corporate Catalyst Neutral Impact 55
Natera Reports Key Findings from ESMO Congress 2026
Natera's 8-K filing details the significant presence of its cell-free DNA technology at the 2026 ESMO Congress, with 25 abstracts and 9 oral presentations, including Phase III tria…
Oct 23, 2026 Corporate Catalyst Neutral Impact 65
Roth Capital Partners Initiates Coverage on Natera, Inc. with Buy Rating
Roth Capital Partners has initiated coverage on Natera, Inc. with a 'Buy' rating and a $475 price target. This event is significant as new analyst coverage, especially with a posit…
Oct 23, 2026 Corporate Catalyst Neutral Impact 65
Roth MKM Initiates Coverage of Natera with Buy Rating
Roth MKM has initiated coverage on Natera (NTRA), a clinical genetic testing company, with a 'Buy' rating and an ambitious price target of $475. This analyst initiation is a positi…
Oct 19, 2026 Corporate Catalyst Bullish Impact 85
Reported Sunday, Natera Will Unveil SAGITTARIUS Phase III Data At ESMO 2026 Showing Signatera Results Changed Treatment Plans For One In Three Colon Cancer Patients, Of Which 87% De-Escalated On MRD Negativity
This headline signals a major positive catalyst for Natera. The SAGITTARIUS Phase III data, particularly the high rate of treatment de-escalation based on MRD negativity, suggests …
Oct 13, 2026 Corporate Catalyst Bullish Impact 65
Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $435
Morgan Stanley analyst Tejas Savant maintained an 'Overweight' rating on Natera and significantly raised the price target from $355 to $435. This upgrade signals strong analyst con…
Oct 13, 2026 Corporate Catalyst Bullish Impact 65
TD Cowen Maintains Buy on Natera, Raises Price Target to $480
TD Cowen analyst Dan Brennan maintained a 'Buy' rating on Natera (NTRA) and raised the price target from $340 to $480. This substantial increase in the price target, representing a…
Oct 9, 2026 Corporate Catalyst Bullish Impact 75
Natera Receives FDA's Breakthrough Device Designation For Its Multi-Cancer Early Detection Assay
Natera, Inc. announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the FDA. This designation is significant because…
Oct 7, 2026 Corporate Catalyst Bullish Impact 65
Barclays Maintains Overweight on Natera, Raises Price Target to $475
Barclays analyst Luke Sergott has maintained an 'Overweight' rating on Natera and raised the price target from $340 to $475. This substantial increase in the price target, coupled …
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
Citigroup Maintains Buy on Natera, Raises Price Target to $480
Citigroup analyst Albert Hu has maintained a 'Buy' rating on Natera and raised the price target from $365 to $480. This is a significant positive development for Natera, as a highe…
Oct 6, 2026 Corporate Catalyst Bullish Impact 85
Natera Says Signatera Showed 100% Sensitivity, 97% Specificity For Rectal Cancer Recurrence In Data Presented At ASTRO 2026
The headline presents highly positive clinical trial data for Natera's Signatera, a liquid biopsy test. 100% sensitivity and 97% specificity for rectal cancer recurrence are except…
Oct 5, 2026 Corporate Catalyst Bullish Impact 85
Natera shares are trading higher after the company and Alliance Foundation Trials announced the launch of AFT-70 NAVIGATE, a phase III trial evaluating an MRD-guided treatment strategy for early breast cancer.
The launch of a Phase III trial, especially one evaluating a 'guided treatment strategy,' is a significant corporate catalyst for a biotechnology company. Success in AFT-70 NAVIGAT…
Oct 1, 2026 Corporate Catalyst Bullish Impact 65
Guggenheim Maintains Buy on Natera, Raises Price Target to $475
Guggenheim analyst Subbu Nambi has raised the price target for Natera (NTRA) from $360 to $475 while maintaining a 'Buy' rating. This action indicates a strengthened positive outlo…
Sep 25, 2026 Corporate Catalyst Neutral Impact 75
Live On CNBC, Kevin Simpson Announces Bought Natera
Kevin Simpson's public announcement of buying Natera (NTRA) on CNBC is a significant corporate catalyst. Such endorsements from well-known investors often lead to increased buying …
Sep 25, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Maintains Outperform on Natera, Raises Price Target to $460
RBC Capital analyst Dan Leonard has maintained an 'Outperform' rating on Natera (NTRA) and raised the price target from $350 to $460. This is a significant upgrade in the price tar…
Sep 22, 2026 Corporate Catalyst Bullish Impact 85
Natera shares are trading higher. The company announced that Japan's pharma and medical devices agency has approved its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.
This approval is a significant positive catalyst for Natera, opening up a new and substantial market for its Signatera test in muscle-invasive bladder cancer. The 'companion diagno…
Sep 9, 2026 Corporate Catalyst Bullish Impact 65
UBS Maintains Buy on Natera, Raises Price Target to $435
UBS analyst Doug Schenkel has maintained a 'Buy' rating on Natera and raised the price target from $290 to $435. This substantial increase in the price target, by over 50%, indicat…
Sep 8, 2026 Corporate Catalyst Neutral Impact 65
Rothschild & Co Initiates Coverage On Natera with Buy Rating, Announces Price Target of $385
Rothschild & Co's initiation of coverage on Natera with a 'Buy' rating and a $385 price target is a positive development for the company. Analyst coverage, especially with a strong…
Sep 1, 2026 Corporate Catalyst Bullish Impact 75
Natera Reports Signatera Helped Predict Lymphoma Outcomes And Treatment Response
Natera's 8-K filing details the publication of new data in 'Blood Neoplasia' demonstrating Signatera's superior ability to predict lymphoma outcomes and treatment response compared…
Aug 13, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Natera, Raises Price Target to $365
This filing discloses that Citigroup, through its analyst Brendan Digan, has maintained a 'Buy' rating on Natera and raised its price target from $315 to $365. This is significant …
Aug 12, 2026 Corporate Catalyst Bullish Impact 65
Piper Sandler Maintains Overweight on Natera, Raises Price Target to $363.5
Piper Sandler analyst David Westenberg has maintained an 'Overweight' rating on Natera (NTRA) and substantially raised the price target from $249 to $363.5. This significant increa…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
Stephens & Co. Maintains Overweight on Natera, Raises Price Target to $350
Stephens & Co. analyst Mason Carrico has maintained an 'Overweight' rating on Natera and raised the price target from $305 to $350. This indicates a strong belief in the company's …
Aug 12, 2026 Corporate Catalyst Bullish Impact 65
Guggenheim Maintains Buy on Natera, Raises Price Target to $360
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Natera and significantly raised the price target from $290 to $360. This action indicates a strong positive outlook from…
Aug 7, 2026 Corporate Catalyst Bullish Impact 65
TD Cowen Maintains Buy on Natera, Raises Price Target to $340
TD Cowen analyst Dan Brennan maintained a 'Buy' rating on Natera (NTRA) and raised the price target from $325 to $340. This action signals a strengthened positive outlook from a pr…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Natera, Raises Price Target to $315
Citigroup analyst Brendan Digan maintained a 'Buy' rating on Natera and raised the price target from $300 to $315. This action signals a continued bullish outlook from a major inve…
Aug 7, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Maintains Outperform on Natera, Raises Price Target to $350
RBC Capital's analyst Dan Leonard maintained an Outperform rating on Natera and significantly raised the price target from $275 to $350. This action signals strong conviction from …
Aug 7, 2026 Corporate Catalyst Bullish Impact 85
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
The filing highlights a strong day for several individual stocks, primarily driven by robust earnings reports and optimistic forward guidance. Natera, Doximity, PubMatic, and Airbn…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Natera, Raises Price Target to $360
JP Morgan analyst Casey Woodring maintained an 'Overweight' rating on Natera and raised the price target from $315 to $360. This action signals a positive outlook from a major inve…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
Wells Fargo Maintains Equal-Weight on Natera, Raises Price Target to $284
Wells Fargo analyst Evan Stampler maintained an 'Equal-Weight' rating on Natera but raised the price target from $220 to $284. This indicates that while the analyst believes the st…
Aug 7, 2026 Corporate Catalyst Bullish Impact 65
Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $360
Evercore ISI Group analyst Daniel Markowitz maintained an Outperform rating on Natera (NTRA) and raised the price target from $300 to $360. This upgrade signals increased confidenc…
Aug 7, 2026 Corporate Catalyst Bullish Impact 92
Natera shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, BTIG raised its price target on the stock from $290 to $320.
This headline is a major positive catalyst for Natera (NTRA). The combination of beating Q2 expectations and significantly raising long-term sales guidance (FY26) signals robust bu…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on Natera, Raises Price Target to $320
BTIG analyst Mark Massaro has maintained a 'Buy' rating on Natera (NTRA) and raised the price target from $290 to $320. This action signals continued confidence from the analyst in…
Aug 6, 2026 Corporate Catalyst Bullish Impact 92
Natera shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
This headline represents a major positive corporate catalyst for Natera. The combination of exceeding current quarter expectations and significantly increasing long-term sales guid…
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Natera Raises FY2026 Sales Guidance from $2.740B-$2.820B to $2.850B-$2.910B vs $2.797B Est
Natera (NTRA) has updated its financial outlook for fiscal year 2026, raising its sales guidance from a range of $2.740 billion-$2.820 billion to $2.850 billion-$2.910 billion. Thi…
Aug 6, 2026 Corporate Catalyst Bullish Impact 95
Natera Q2 EPS $(0.47) Beats $(0.51) Estimate, Sales $752.750M Beat $660.687M Estimate
Natera's Q2 earnings report shows a significant beat on both EPS and sales estimates. The company reported losses of $(0.47) per share, beating the $(0.51) estimate, and sales of $…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Natera Submits Application To Japan’s Pharmaceuticals And Medical Devices Agency For Approval Of The Signatera Test In Muscle-Invasive Bladder Cancer As A Companion Diagnostic
Natera has filed an application with Japan's PMDA for its Signatera test in muscle-invasive bladder cancer, building on its prior approval in colorectal cancer. This move signifies…
Jul 22, 2026 Corporate Catalyst Bullish Impact 65
Natera Publishes Results From Prospective, Multicenter Study In Merkel Cell Carcinoma In The JAMA Dermatology Journal; Signatera Test Was A Significantly Stronger Predictor Of Recurrence Than AMERK
Natera published results from a prospective, multicenter study in JAMA Dermatology, highlighting the superior performance of its Signatera test over the AMERK test in predicting Me…
Jul 17, 2026 Corporate Catalyst Bullish Impact 75
Reported Earlier, Natera Highlights Finalized MolDx LCD Expanding Prospera Testing Coverage Across Kidney, Heart, And Lung Transplant Surveillance Settings
The finalized MolDx LCD expanding Prospera testing coverage is a major positive catalyst for Natera. This regulatory approval significantly broadens the addressable market for thei…
Jul 14, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on Natera, Raises Price Target to $330
Canaccord Genuity analyst Kyle Mikson maintained a 'Buy' rating on Natera and raised the price target from $285 to $330. This action signals increased confidence from the analyst i…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.